Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37
Oslo, Norway, 30 November 2021 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be held via a live webcast. Presentations will be delivered by Dr Leo I. Gordon, MD, FACP, a global key opinion leader in haematology and members of Nordic Nanovector’s executive team. Erik Skullerud, Nordic Nanovector’s CEO, commented: “We are pleased to share our vision and strategy for creating value from